GlaxoSmithKline Pharmaceuticals Stock
GlaxoSmithKline Pharmaceuticals (GLAXO.NS) has a MEQIRI Score of 74 out of 100 (Strong) as of 22 Nov 2026. At the 20 Nov 2026 close of $29.43, the stock trades 105% above its fair value of $14.36 according to our model.
GLAXO.NSNSEGlaxoSmithKline Pharmaceuticals Limited, HealthcareISIN INE159A01016
Price and Trend
80 / 100
Price history
+8.3% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 7.7% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is 12% below its 52-week high. Largest decline in 20 years: 45% (March 2016 to March 2018).
Chart figures for advanced users
- SMA 50$28.67
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$27.33
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.69
- The lowest closing price of the last twelve months.
- Resistance$33.52
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GlaxoSmithKline Pharmaceuticals Limited belongs to the Drug Manufacturers (General) industry (India) and, with a market value of $4.99B, is number 26 of 28 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $412.37M (up 2.6% year on year) and earnings of $111.79M (up 11.7%).
- For fiscal 2027, analysts expect on average revenue of $469.17M (up 13.8%) and adjusted earnings per share of $0.76 (up 17.8%).
Show more
- MEQIRI Score 74 out of 100 (Strong): rank 69 of 681 in Healthcare, median 53.
- The P/E is 40.3 (Drug Manufacturers (General) median 17.3, own median of recent years 50.8).
- Our model puts fair value at $14.36, with the price 105% above it.
In Plain Words
The numbers on this page in plain words, written by an AI
Strengths
- High Return on CapitalReturn on invested capital 39.1% in fiscal 2026, Healthcare sector median 9.2%.Profitability 95
- More Cash than DebtCash $239.39M, financial debt $4.24M.Stability 89
- Earnings per Share GrowingUp 23.7% a year since 2021.Growth 58
Weaknesses
- Above Fair ValuePrice 105% above the fair value of $14.36.Valuation 20
Its standout strengths are profitability and stability, while valuation holds the score back.
Daily figure as of 22 Nov 2026
How the score is calculatedScore Overview
Fundamentals are strong, with stable profits.
Score History
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash Risk not measured
How Well MEQIRI WarnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation Signal
Significantly overvaluedIn our model the price counts as cheap below $11.04 and expensive above $20.51 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $16.09 (cash-flow model) and $12.63 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $13.12, at 11.6% it would be $16.13.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (17.3).
Calculate with your own assumptionsCompany Performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 12.8% on the twelve months before. Revenue has grown solidly since 2007, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 44%, operating 33%, net 27%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 15 Feb 2027in 85 days
- Last reported
- 3 Nov 2026EPS reported $0.21 (expected $0.18)above expectations
What Happened at GlaxoSmithKline Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector Comparison
681 rated companies in Healthcare
- This company
- 74
- Sector median
- 53
Categories Against the Sector Median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
ETFs That Hold GlaxoSmithKline Pharmaceuticals
Held by 4 of the 100 largest US ETFs. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Vanguard FTSE Emerging Markets ETFVWO | 0.01% | 0.06% | $117.5B |
| iShares Core MSCI Emerging Markets ETFIEMG | 0.01% | 0.09% | $129.62B |
| iShares Core MSCI Total International Stock ETFIXUS | 0.00% | 0.07% | $52.59B |
Show 1 more
| Vanguard Total International Stock ETFVXUS | 0.00% | 0.05% | $160.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data Status and Sources
- Score
- Daily value of 22 Nov 2026, recalculated nightly
- Price
- Closing price of 20 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory Disclosures for This Rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 30 Oct 2026)
- Valuation signal Overvalued since 22 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
